The SA Journal Diabetes & Vascular Disease Vol 11 No 4 (November 2014)

25 / 44

VOLUME 11 NUMBER 4 • NOVEMBER 2014 159
SA JOURNAL OF DIABETES & VASCULAR DISEASE REVIEW
70. Liu ML, Ylitalo K, Vakkilainen J, et al . Susceptibility of LDL to oxidation in vitro
and antioxidant capacity in familial combined hyperlipidemia: comparison of
patients with different lipid phenotypes. Ann Med 2002; 34: 48–54. http://
dx.doi.org/10.1080/078538902317338643
71. Moro E, Alessandrini P, Zambon C, et al. Is glycation of low density lipoproteins
in patients with Type 2 diabetes mellitus a LDL pre-oxidative condition? Diabetic
Med 1999; 16: 663–669.
72. Assmann G, Schulte H, Cullen P, et al. Assessing risk of myocardial infarction
and stroke: new data from the Prospective Cardiovascular Munster (PROCAM)
study. Eur J Clin Invest 2007; 37: 925–932. 10.1111/j.1365-
2362.2007.01888.x
73. Assmann G, Schulte H, Seedorf U. Cardiovascular risk assessment in the metabolic
syndrome: results from the Prospective Cardiovascular Munster (PROCAM)
Study. Int J Obes (Lond) 2008; 32(Suppl 2): S11–S16.
ijo.2008.29
74. Sarwar N, Danesh J, Eiriksdottir G, et al. Triglycerides and the risk of coronary
heart disease: 10,158 incident cases among 262,525 participants in 29 Western
prospective studies. Circulation 2007; 115: 450–458.
CIRCULATIONAHA.106.637793
75. Jiang R, Schulze MB, Li T, et al. Non-HDL cholesterol and apolipoprotein B predict
cardiovascular disease events among men with type 2 diabetes. Diabetes Care
2004; 27: 1991–1997. 27.8.1991
76. Bansal S, Buring JE, Rifai N, et al. Fasting compared with nonfasting triglycerides
and risk of cardiovascular events in women. J Am Med Assoc 2007; 298: 309–
316.
77. Nordestgaard BG, Benn M, Schnohr P, et al. Nonfasting triglycerides and risk of
myocardial infarction, ischemic heart disease, and death in men and women. J Am
Med Assoc 2007; 298: 299–308.
78. Boekholdt SM, Arsenault BJ, Mora S, et al. Association of LDL cholesterol, non-
HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events
among patients treated with statins: a meta-analysis. J Am Med Assoc 2012; 307:
1302–1309.
79. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of
cardiovascular disease in type 2 diabetes. Diabetes Care 2003; 26: 16–23.
80. Jenkins AJ, Rowley KG, Lyons TJ, et al. Lipoproteins and diabetic microvascular
complications. Curr Pharm Des 2004; 10: 3395–3418. .
org/10.2174/1381612043383188
81. Chew EY, Klein ML, Ferris FL, III, et al. Association of elevated serum lipid levels
with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic
Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996; 114: 1079–1084.
82. Ucgun NI, Yildirim Z, Kilic N, et al. The importance of serum lipids in exudative
diabetic macular edema in type 2 diabetic patients. Ann NY Acad Sci 2007; 1100:
213–217. 1395.021
83. Chowdhury TA, Hopkins D, Dodson PM, et al . The role of serum lipids in
exudative diabetic maculopathy: is there a place for lipid lowering therapy? Eye
(Lond) 2002; 16: 689–693. 84. Davis
MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic
retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study
Report #18. Invest Ophthalmol Vis Sci 1998; 39: 233–252.
85. Lyons TJ, Jenkins AJ, Zheng D, et al. Diabetic retinopathy and serum lipoprotein
subclasses in the DCCT/EDIC cohort. Invest Ophthalmol Vis Sci 2004; 45: 910–
918.
86. Retnakaran R, Cull CA, Thorne KI, et al. Risk factors for renal dysfunction in type
2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes 2006; 55: 1832–189.
87. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic
neuropathy. N Engl J Med 2005; 352: 341–350.
NEJMoa032782
88. Kempler P, Tesfaye S, Chaturvedi N, et al. Autonomic neuropathy is associated
with increased cardiovascular risk factors: the EURODIAB IDDM Complications
Study. Diabet Med 2002; 19: 900–909.
5491.2002.00821.x
89. Collins R, Armitage J, Parish S,et al. MRC/BHF Heart Protection Study of cholesterol-
lowering with simvastatin in 5963 people with diabetes: a randomised placebo-
controlled trial. Lancet 2003; 361: 2005–2016.
S0140-6736(03)13636-7
90. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of
cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative
Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-
controlled trial. Lancet 2004; 364: 685–696. 10.1016/S0140-
6736(04)16895-5
91. Kearney PM, Blackwell L, Collins R, et al. Efficacy of cholesterol-lowering therapy
in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis.
Lancet 2008; 371: 117–125. (08)60104-X
92. Frikke-Schmidt R, Nordestgaard BG, Stene MC, et al. Association of loss-of-
function mutations in the ABCA1 gene with high-density lipoprotein cholesterol
levels and risk of ischemic heart disease. J Am Med Assoc 2008; 299: 2524–2532.
93. Johannsen TH, Kamstrup PR, Andersen RV, et al. Hepatic lipase, genetically
elevated high-density lipoprotein, and risk of ischemic cardiovascular disease. J
Clin Endocrinol Metab 2009; 94: 1264–1273. 10.1210/jc.2008-
1342
94. Haase CL, Tybjaerg-Hansen A, Qayyum AA, et al. LCAT, HDL cholesterol and
ischemic cardiovascular disease: a Mendelian randomization study of HDL
cholesterol in 54,500 individuals. J Clin Endocrinol Metab 2012; 97: E248–E256.
95. Voight BF, Peloso GM, Orho-Melander M, et al. Plasma HDL cholesterol and risk
of myocardial infarction: a mendelian randomisation study. Lancet 2012; 380:
572–580. 12) 60312-2
96. Johansen CT, Hegele RA. Using Mendelian randomization to determine causative
factors in cardiovascular disease. J Intern Med 2013; 273: 44–47.
org/10.1111/j.1365-2796.2012.02586.x
97. Boden WE, Probstfield JL, Anderson T, et al. Niacin in patients with low HDL
cholesterol levels receiving intensive statin therapy. N Engl J Med 2011; 365:
2255–2267.
98. HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of
ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and
reasons for stopping study treatment. Eur Heart J 2013; 34: 1279–1291. http://
dx.doi.org/10.1093/eurheartj/eht055
99. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high
risk for coronary events. N Engl J Med 2007; 357: 2109–2122.
org/10.1056/NEJMoa0706628
100. Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a
recent acute coronary syndrome. N Engl J Med 2012; 367: 2089–2099. http://
dx.doi.org/10.1056/NEJMoa1206797
101. Khera AV, Cuchel M, Llera-Moya M, et al. Cholesterol efflux capacity, high-density
lipoprotein function, and atherosclerosis. N Engl J Med 2011; 364: 127–135.
102. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at
high risk for coronary heart disease. N Engl J Med 2010; 363: 2406–2415. http://
dx.doi.org/10.1056/NEJMoa1009744
103. Nicholls SJ, Brewer HB, Kastelein JJ, et al. Effects of the CETP inhibitor evacetrapib
administered as monotherapy or in combination with statins on HDL and LDL
cholesterol: a randomized controlled trial. J Am Med Assoc 2011; 306: 2099–
2109.
104. ClinicalTrials.gov. NCT01252953: REVEAL: Randomised evaluation of the effects
of anacetrapib through lipid modification. 2012. ClinicalTrials.gov.
105. ClinicalTrials.gov. NCT01687998: A study of evacetrapib in high-risk vascular
disease (ACCELERATE). 2012. ClinicalTrials.gov.
106. Tenenbaum A, Fisman EZ, Motro M, et al. Optimal management of combined
dyslipidemia: what have we behind statins monotherapy? Adv Cardiol 2008; 45:
127–153.
107. Wilding JP, Gause-Nilsson I, Persson A. Tesaglitazar, as add-on therapy to
sulphonylurea, dose-dependently improves glucose and lipid abnormalities in
patients with type 2 diabetes. Diab Vasc Dis Res 2007; 4: 194–203. .
org/10.3132/dvdr.2007.040
108. Long GG, Reynolds VL, Lopez-Martinez A, et al. Urothelial carcinogenesis in the
urinary bladder of rats treated with naveglitazar, a gammadominant PPAR alpha/
gamma agonist: lack of evidence for urolithiasis as an inciting event. Toxicol
Pathol 2008; 36: 218–231.
109. Nissen SE, Wolski K, Topol EJ. Effect of muraglitazar on death and major adverse
cardiovascular events in patients with type 2 diabetes mellitus. J Am Med Assoc
2005; 294: 2581–2586.
110. Henry RR, Lincoff AM, Mudaliar S, et al. Effect of the dual peroxisome proliferator-
activated receptor-alpha/gamma agonist aleglitazar on risk of cardiovascular
disease in patients with type 2 diabetes (SYNCHRONY): a phase II, randomised,
dose-ranging study. Lancet 2009; 374: 126–135.
S0140-6736(09)60870-9
111. Roche press release: Roche halts investigation of aleglitazar following regular
safety review of phase III trial. 2010.
112. Fruchart JC. Selective peroxisome proliferator-activated receptorα modulators
(SPPARMα): The next generation of peroxisome proliferator-activated receptor
α-agonists. Cardiovasc Diabetol 2013; 12: 82.
2840-12-82